FILANA THERAPEUTICS
LIVE

Serial Number

99602139

Owner

FILANA THERAPEUTICS, INC.

Attorney

Alexandra H. Bistline

Filing Date

Jan 19, 2026

Add to watchlist:

No watchlists yet
View on USPTO

FILANA THERAPEUTICS Trademark

Serial Number: 99602139

FILANA THERAPEUTICS is a trademark filed by FILANA THERAPEUTICS, INC. on January 19, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

FILANA THERAPEUTICS, INC.

6801 N. CAPITAL OF TEXAS HIGHWAY
AUSTIN, TX 78731

Entity Type: 03

Cassava Sciences, Inc.

Blgd 1, Suite 300; 6801 N. Capital of Texas Highway
Austin, TX 78731

Entity Type: 03

Trademark Details

Filing Date

January 19, 2026

Registration Date

Not Registered

Published for Opposition

June 16, 2026

Goods & Services

Medical research services; Scientific research; Providing medical and scientific research information; Medical and scientific research in the field of neurologic and neuropsychiatric disorders, neurodegenerative diseases and developmental disorders, and in the fields of oncologic diseases, metabolic diseases, and pain; Pharmaceutical research and development; Pharmaceutical product evaluation; Technical consulting in the field of pharmaceutical studies; Laboratory research services relating to pharmaceuticals; Testing of pharmaceuticals; Laboratory services for the production of pharmaceuticals in the nature of pharmaceuticals for treating neurologic and neuropsychiatric disorders, neurodegenerative diseases and developmental disorders, and for treating oncologic diseases, metabolic diseases, and pain, and pharmaceuticals as analgesic preparations and preparations for pain relief

Pharmaceutical advice; Providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; Providing medical information; Providing medical information in the field of neurologic and neuropsychiatric disorders, neurodegenerative diseases and developmental disorders, and in the fields of oncologic diseases, metabolic diseases, and pain

Pharmaceutical preparations for the treatment of neurologic and neuropsychiatric disorders, neurodegenerative diseases and developmental disorders, and for the treatment of oncologic diseases, metabolic diseases, and pain; Analgesic preparations; Preparation for the relief of pain

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 26, 2026 ASGN
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 11, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 16, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jun 16, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 10, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 20, 2026 CNSA
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 20, 2026 GNEN
EXAMINER'S AMENDMENT ENTERED
May 20, 2026 XAEC
EXAMINERS AMENDMENT E-MAILED
May 20, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 20, 2026 CNEA
ASSIGNED TO EXAMINER
May 15, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 21, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Jan 19, 2026 MAFR
NEW APPLICATION ENTERED
Jan 19, 2026 NWAP